Previous close | 4.2900 |
Open | 2.5000 |
Bid | 1.1500 |
Ask | 6.8000 |
Strike | 195.00 |
Expiry date | 2026-01-16 |
Day's range | 1.1500 - 6.8900 |
Contract range | N/A |
Volume | |
Open interest | 27 |
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.